🇬🇧 đŸ‡«đŸ‡·
I

Immunovant

Biotechnology Research · United States · 500 employees

Biotechnology Research United States B2B Est. 2018
121 Decision makers
+4 New (6 months)
500 Employees
2018 Founded

Organizational Chart of Immunovant

Roles identified within Immunovant's leadership team, from public professional data, updated 25 Oct 2026.

Department

Immunovant's Full Organizational Chart

Loading


Get their contacts on Zeliq →

Job title Department People

Decision makers at Immunovant by function

General management

Tech & product

See all Immunovant contacts on Zeliq

Decision makers at Immunovant

121 identified 6 C-Level 12 VP 103 Directors +4 new (6 months)
See them on Zeliq →

Departments actively hiring 2 departments

Finance & accounting
Research

These departments at Immunovant are actively recruiting: a strong signal to time your outreach.

Funding and news at Immunovant

Funding

Last round Other · $550M
Total funding $1.9B (7 rounds)
Venture Round $40M Jul 2019
Post-IPO Equity $139M Apr 2020
Post-IPO Equity $200M Aug 2021
Post-IPO Equity $75M Oct 2022
Post-IPO Equity $450M Sep 2023
Post-IPO Equity $450M Jan 2025
Post-IPO Equity $550M Dec 2025

Latest news at Immunovant

  1. Appointment

    New Executive Medical Director appointed — Medical

  2. Appointment

    New Director, Tmf Operations appointed — Operations

  3. Appointment

    New Chief Strategy Officer appointed — General management

  4. Appointment

    New Senior Director, Clinical Pharmacology appointed — Medical

Get these new hires' email and phone →

Team Structure headcount by department

Medical
59
Project Management
27
General Management
26
Hiring Research
25
Operations
22
Other
22
Hiring Finance
14
Legal
14

How to prospect Immunovant's departments
Medical

The company's largest department, with 59 people. Medical teams trust peer references: name comparable organisations you already serve.

Project Management

The company's second-largest department (27 people). These profiles own delivery: anything that de-risks a milestone gets their attention.

General Management

A team of 26 people. A good executive approach often starts lower in the organisation: build an internal champion before going top-down.

Research

A team of 25 people, currently hiring. Researchers respond to substance: reference publications, benchmarks or datasets relevant to their field.

Operations

This department counts 22 people. Operations leaders live in the concrete: a pilot scoped on one process will convince more than a demo.

Finance

This 14-person department is actively recruiting. Timing matters here: approach them around budget planning cycles, when arbitrations are actually open.

Try the Zeliq email finder demo →

FAQ Immunovant

Who runs Immunovant?

The highest-ranking leadership role identified at Immunovant is “CTO”, based on public data updated 25 Oct 2026.

How many decision makers does Immunovant have?

121 decision makers identified, including 6 at executive level.

How do I contact a decision maker at Immunovant?

Verified emails and phone numbers are available in Zeliq, with free credits at sign-up.

Which departments are hiring at Immunovant?

Finance & accounting and Research, based on published job offers as of 25 Oct 2026.

Companies similar to Immunovant

More companies to explore

Biotechnology Research · United States

All Biotechnology Research companies in United States →

About Immunovant

Immunovant operates in the Biotechnology Research industry, based in United States. The company was founded in 2018 and employs approximately 500 people. Immunovant belongs to the Professional Services sector, with a specific positioning on Biotechnology Research. Immunovant sells primarily to other businesses (B2B) rather than to end consumers. Immunovant has raised funding across 7 rounds totalling $1.9B. This profile compiles key information about Immunovant, including industry, size, location, business signals, and B2B contacts, to help sales teams qualify the account and identify the right decision makers before reaching out.

Activity & Market

Immunovant operates in the Biotechnology Research segment, part of the broader Professional Services sector. As a B2B company, Immunovant primarily serves business clients and professional organisations. In terms of structure, it is registered as “Public company”.